- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01708850
Study in Cancer Patients With Central Line Associated Clots in the Upper Extremity Treated With Rivaroxaban (Catheter 2)
A Pilot Study in Cancer Patients With Central Venous Catheter Associated Deep Vein Thrombosis in the Upper Extremity Treated With Rivaroxaban (Catheter 2)
Patients with cancer and an upper extremity DVT associated with a central venous catheter (CVC) will receive rivaroxaban. CVC survival will be assessed and compared to previous rates with low molecular weight heparin (LMWH) and warfarin, along with secondary safety outcomes including bleeding and recurrent venous thromboembolism.
The investigators hypothesize that anticoagulation with rivaroxaban in patients with UEDVT secondary to central venous catheters in patients with active malignancy is an effective therapy as quantified by the success of catheter preservation. Prolonged line salvage rate without recurrence of UEDVT will improve the management of cancer patients who develop an upper extremity deep venous thrombosis in the setting of a central venous catheter.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This will be a prospective cohort study of patients who present with an acute upper limb thrombosis in the setting of a central venous catheter. The total study duration will be 12 weeks, with one follow up telephone visit at 6 months. All patients will be treated with rivaroxaban at a dose of 15 mg orally twice daily for three weeks, followed by 20 mg daily. Anticoagulation will continue for three months regardless of the length of time the catheter is in place. Continuation of anticoagulation beyond this time period is at the discretion of the investigators.
Strengths of this study include its prospective cohort format, and access to a large oncologic population through the London Regional Cancer Program and other corresponding centres. In addition, The Catheter Study looking at CVC survival and safety in patients with cancer diagnosed with UEDVT and treated with a bridging protocol of warfarin/dalteparin was organized primarily through the LHSc and results therein could be directly compared to the results from this study given the similar patient population.
Limitations of this study include the small sample size and the fact that there is no LMWH monotherapy comparison group. In addition, this will be an open study with no blinding, given the nature of line survival. There is also the chance that a proportion of patients will have their catheters removed for other reasons, such as finishing treatment or personal preference, which could affect the validity of survival results.
This design was selected given the small number of patients presenting with this diagnosis each year at our centre, which would present difficulty in accruing enough patients for several comparisons group. Results will be compared to the Catheter Study and previous literature.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A5W9
- London Health Sciences Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female > 18 years of age.
- Symptomatic acute upper limb thrombosis in the axillary, subclavian, innominate or internal jugular veins, with or without pulmonary embolism, associated with central venous catheter objectively documented by compression ultrasonography, venogram or CT scan.
- Diagnosis of active malignancy (other than non-melanoma skin cancer), defined as patients who are either receiving active treatment, or have metastatic disease or who have been diagnosed within the past two years.
- Willing to provide written informed consent.
Exclusion Criteria:
- Dialysis catheters.
- Active bleeding or high risk for major bleeding.
- Platelet Count < 75 x 109/L.
- Creatinine Clearance < 30 mL/min.
- Currently on other anticoagulant with therapeutic intent for another indication.*
- Pulmonary embolism accompanied by hemodynamic instability or oxygen requirement.
- Inability to infuse through the catheter after a trial of intraluminal thrombolytic therapy (ie. 2 mg tPA).
- Patients with AML, ALL or multiple myeloma with a bone marrow or stem cell transplant planned within the next 3 months.
- Thrombosis involving the brachial or cephalic veins only.
- Treatment for current episode > 7 days with any acceptable anticoagulant therapy.
- Concomitant use of P-glycoprotein and CYP3A4 inhibitors (ie. azole antifungals such as ketoconazole) or inducers (ie. rifampicin, antiepileptics).*
- Recent coronary artery stent requiring dual anti-platelet therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Rivaroxaban
Rivaroxaban 15 mg po bid x 3 weeks, followed by rivaroxaban 20 mg po daily x 9 weeks.
Then up to discretion of investigator to decide regarding further anticoagulation as study length is limited to 12 weeks.
|
All specified in arm description.
One arm study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of central line failure, defined as infusion failure that does not respond to 2mg tPA.
Time Frame: 12 weeks
|
The primary endpoint of the study will be proportion of central line failure, defined as infusion failure that does not respond to 2mg tPA, within the 3 months of study follow-up.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Recurrence of DVT or PE
Time Frame: 12 weeks
|
12 weeks
|
Major Bleeding
Time Frame: 12 weeks
|
12 weeks
|
Clinically Relevant Non-Major Bleeding
Time Frame: 12 weeks
|
12 weeks
|
Death
Time Frame: 12 weeks
|
12 weeks
|
Time to Central Line Failure
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dr. Michael J. Kovacs, MD, FRCPC, London Health Sciences Centre
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Embolism and Thrombosis
- Venous Thrombosis
- Thrombosis
- Upper Extremity Deep Vein Thrombosis
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Factor Xa Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Rivaroxaban
Other Study ID Numbers
- Catheter 2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Central Venous Catheter Thrombosis
-
Fraser HealthSterileCare Inc.; Center for Health Evaluation & Outcome ServicesRecruitingCentral Venous Catheter Thrombosis | Catheter Infection | Catheter Complications | Catheter | Catheter Blockage | Catheter Dysfunction | Central Line-associated Bloodstream Infection (CLABSI) | Central Venous Catheter Related Bloodstream InfectionCanada
-
Zhujiang HospitalUnknownCentral Venous Catheter Thrombosis | Catheter-Related Infections | Catheter Thrombosis | Central Venous Catheter Related Bloodstream InfectionChina
-
Policlinico HospitalCompletedCentral Venous Catheter Thrombosis | Intensive Care Unit | Thrombosis, Venous | Central Venous CathetersItaly
-
University of Texas Southwestern Medical CenterTerminatedDeep Vein Thrombosis | Childhood Cancer | Central Venous Catheters | Catheter-related Infection | Catheter-related OcclusionUnited States
-
Second Affiliated Hospital, School of Medicine,...UnknownCentral Venous Catheter ThrombosisChina
-
Medical University of ViennaCompletedCentral Venous Catheter ThrombosisAustria
-
Amsterdam UMC, location VUmcCompletedCentral Venous Catheter ThrombosisNetherlands
-
Chang Gung Memorial HospitalEnrolling by invitationCentral Venous Catheter Thrombosis | Renal DialysisTaiwan
-
Guangdong Provincial People's HospitalCompletedCardiac Surgery | Central Venous Catheter Thrombosis | HeparinChina
-
Medical College of WisconsinCompletedCentral Venous Catheter Thrombosis | Central Venous Catheter Associated Bloodstream InfectionUnited States
Clinical Trials on Rivaroxaban
-
Portola PharmaceuticalsCompleted
-
Korea University Anam HospitalRecruitingAtrial Fibrillation | Anticoagulant Adverse ReactionKorea, Republic of
-
Doasense GmbHActive, not recruitingAnticoagulant TherapyGermany
-
China National Center for Cardiovascular DiseasesNot yet recruitingStroke | Atrial Fibrillation | Major Adverse Cardiac Events | Anticoagulant Adverse Reaction
-
BayerCompleted
-
The Affiliated Hospital of Qingdao UniversityCompletedHealthy SubjectsChina
-
BayerJanssen R&D, L.L.C.Completed
-
BayerJanssen Research & Development, LLCCompletedCoronary Artery Disease | Cardiovascular DiseaseBelgium, Netherlands
-
University Hospital, GrenobleCompleted
-
Addpharma Inc.CompletedEmbolism and ThrombosisKorea, Republic of